Abstract: Slide Presentations |

Global ENHANCE Results Indicate Organ Function Improvement With Drotrecogin Alfa (activated) in Severe Sepsis Patients FREE TO VIEW

Jean-Louis Vincent, MD, PhD, FCCP; Bruce Light, MD; Theressa Wright, MD; Kar Wong, PhD; Gerald Johnson, PhD; Gordon Bernard, MD, FCCP
Author and Funding Information

Erasme Hospital, Brussels, Belgium


Chest. 2003;124(4_MeetingAbstracts):103S. doi:10.1378/chest.124.4_MeetingAbstracts.103S
Text Size: A A A
Published online


PURPOSE:  Rotrecogin alfa (activated) [DrotAA] significantly reduced mortality and improved organ function in severe sepsis patients (PROWESS Study; n=1690). We now report sequential organ failure assessment (SOFA) scores from 2378 patients enrolled in a global, single-arm, open-label trial of DrotAA in adult patients with severe sepsis (ENHANCE Study).

METHODS:  Inclusion and exclusion criteria were virtually identical to PROWESS. Patients eligible for participation had known or suspected infection, 3 or 4 of the criteria defining the systemic inflammatory response syndrome, and 1 or more acute (<48 hr duration) organ dysfunctions. Patients at high risk for bleeding were excluded from participation. Organ function was assessed daily using a modified SOFA score. Time-averaged SOFA scores for Days 1–28, adjusted for imbalances in SOFA scores at baseline, are reported.

RESULTS:  VariableENHANCE (DrotAA) [n = 2378]PROWESS (DrotAA) [n = 850]PROWESS (Placebo) [n = 840]SOFA scores at baseline (mean (SEM))Cardiovascular3.01 (0.03)2.61 (0.05)2.69 (0.05)*Respiratory2.73 (0.02)2.65 (0.04)2.70 (0.04)Hepatic0.65 (0.02)0.60 (0.03)0.58 (0.03)Renal1.26 (0.02)1.12 (0.04)1.11 (0.04)*Hematologic0.83 (0.02)0.70 (0.03)0.67 (0.03)*28-day time-averaged SOFA scores (mean (SEM))Cardiovascular1.40 (0.03)1.36 (0.05)1.52 (0.05)*Respiratory2.18 (0.02)2.12 (0.04)2.23 (0.04)Hepatic1.04 (0.03)1.05 (0.05)1.19 (0.05)*Renal1.17 (0.03)1.18 (0.04)1.31 (0.05)*Hematologic1.00 (0.03)1.03 (0.05)1.18 (0.05)*

SEM = standard error of the mean,


= P < 0.05 ENHANCE DrotAA vs. PROWESS Placebo

CONCLUSIONS: Patients in ENHANCE had worse organ dysfunction at baseline compared with placebo patients in PROWESS. Despite the imbalance at baseline, administration of DrotAA was associated with statistically significantly lower time averaged cardiovascular, hepatic, renal and hematologic scores consistent with greater improvement in organ function compared with placebo treated patients.

CLINICAL IMPLICATIONS:  The results of the ENHANCE study confirm the observation in PROWESS that administration of DrotAA is associated with significant improvement in organ function.

DISCLOSURE:  J. Vincent, None. Eli Lilly and Company (Indianapolis, IN) provided support for this research.

Tuesday, October 28, 2003

10:45 AM - 11:45 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543